Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799877 · ClinicalTrials.gov registry record
Chronic Plaque Psoriasis (Ps) Registry
A clinical trial of Chronic Plaque Psoriasis, sponsored by AbbVie.
- Completed
- Registry status
- 6,065
- Enrollment target
- 20
- Study locations
NCT00799877 is a study of Chronic Plaque Psoriasis that has completed, run by AbbVie. The registered enrollment target is 6,065 participants, above the 121-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (4912% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT00799877, a study of Chronic Plaque Psoriasis, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- 6,065 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).
Conditions Studied
Study Locations (20)
Alabama
- Southview Medical Group, PC /ID# 20961 - Birmingham
- Total Skin and Beauty Derm Ctr /ID# 17156 - Birmingham
- Inverness Dermatology /ID# 76194 - Birmingham
- McLain Medical Associates, PC /ID# 18351 - Birmingham
- Deep South Dermatology, PC /ID# 40267 - Daphne
- Northeast Alabama Dermatology /ID# 76193 - Huntsville
- Yates, Huntsville, AL /ID# 17130 - Huntsville
- Mobile Dermatology, P.C. /ID# 19783 - Mobile
Arizona
- Medical Dermatology Specialist /ID# 76113 - Phoenix
- Arizona Advanced Dermatology /ID# 20512 - Phoenix
- Camelback Dermatology & Skin Surgery /ID# 18901 - Phoenix
- Alliance Dermatology and MOHs Center, PC /ID# 17087 - Phoenix
- Omni Dermatology Research /ID# 135562 - Phoenix
- Affiliated Dermatology /ID# 18327 - Scottsdale
- Specialists in Dermatology /ID# 18864 - Tucson
California
- Elite MD Adv Derm Laser /ID# 28323 - Danville
- Center for Dermatology Clinical Research /ID# 20722 - Fremont
- Associates in Research /ID# 17544 - Fresno
Arkansas
- Johnson Dermatology Clinic /ID# 17088 - Fort Smith
- Hull Dermatology, PA /ID# 17086 - Rogers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,065 participants |
| Start Date | 2008-09-26 |
| Est. Completion | 2023-02-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00799877
The ClinicalTrials.gov registry entry for NCT00799877 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6,065 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 121-participant average among 6 other Chronic Plaque Psoriasis trials with a reported enrollment target (4912% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 0 interventions.
NCT00799877 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alabama, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00799877 about?
NCT00799877 is a clinical study titled "Chronic Plaque Psoriasis (Ps) Registry". The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).
What is the current status of trial NCT00799877?
This trial is currently completed. The enrollment target is 6,065 participants. The study started on 2008-09-26. Estimated completion is 2023-02-13.
What conditions does trial NCT00799877 study?
This clinical trial studies the following conditions: Chronic Plaque Psoriasis.
Who is sponsoring clinical trial NCT00799877?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00799877 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
COMPLETED · Phase 4
-
Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 4
-
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.